Design Therapeutics Stock EBITDA
| DSGN Stock | USD 3.65 0.01 0.27% |
Design Therapeutics fundamentals help investors to digest information that contributes to Design Therapeutics' financial success or failures. It also enables traders to predict the movement of Design Stock. The fundamental analysis module provides a way to measure Design Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Design Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -78.2 M | -74.3 M |
Design | EBITDA |
Design Therapeutics Company EBITDA Analysis
Design Therapeutics' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Design Therapeutics EBITDA | (78.19 M) |
Most of Design Therapeutics' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Design Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Design EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Design Therapeutics is extremely important. It helps to project a fair market value of Design Stock properly, considering its historical fundamentals such as EBITDA. Since Design Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Design Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Design Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Design Ebitda
According to the company disclosure, Design Therapeutics reported earnings before interest,tax, depreciation and amortization of (78.19 Million). This is 108.91% lower than that of the Biotechnology sector and 178.07% lower than that of the Health Care industry. The ebitda for all United States stocks is 102.01% higher than that of the company.
Design EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Design Therapeutics' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Design Therapeutics could also be used in its relative valuation, which is a method of valuing Design Therapeutics by comparing valuation metrics of similar companies.Design Therapeutics is currently under evaluation in ebitda category among related companies.
Design Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Design Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Design Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Design Therapeutics' value.| Shares | Geode Capital Management, Llc | 2023-12-31 | 662.7 K | Renaissance Technologies Corp | 2023-12-31 | 648.8 K | Two Sigma Advisers, Llc | 2023-12-31 | 585 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 543.5 K | Two Sigma Investments Llc | 2023-12-31 | 428.2 K | Millennium Management Llc | 2023-12-31 | 420.1 K | Northern Trust Corp | 2023-12-31 | 372.9 K | Walleye Trading Advisors, Llc | 2023-12-31 | 362.4 K | Prescott Group Capital Management Llc | 2023-12-31 | 343 K | Sr One Capital Management, Lp | 2023-12-31 | 6.5 M | Logos Global Management Lp | 2023-12-31 | 5 M |
Design Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (71.98 M) | ||||
| Shares Outstanding | 56.49 M | ||||
| Shares Owned By Insiders | 36.66 % | ||||
| Shares Owned By Institutions | 56.55 % | ||||
| Number Of Shares Shorted | 2.23 M | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 22,642 X | ||||
| Gross Profit | (48.61 M) | ||||
| EBITDA | (78.19 M) | ||||
| Net Income | (66.86 M) | ||||
| Cash And Equivalents | 359.38 M | ||||
| Cash Per Share | 6.45 X | ||||
| Total Debt | 2.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 48.96 X | ||||
| Book Value Per Share | 4.92 X | ||||
| Cash Flow From Operations | (58.56 M) | ||||
| Short Ratio | 7.35 X | ||||
| Earnings Per Share | (1.19) X | ||||
| Target Price | 4.67 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.83 | ||||
| Market Capitalization | 206.77 M | ||||
| Total Asset | 289.64 M | ||||
| Retained Earnings | (177.63 M) | ||||
| Working Capital | 274.96 M | ||||
| Net Asset | 289.64 M |
About Design Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Design Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Design Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Design Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Design Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Design Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Design Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Design Stock
| 0.69 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.75 | ELEV | Elevation Oncology Earnings Call Next Week | PairCorr |
| 0.7 | ACB | Aurora Cannabis Trending | PairCorr |
Moving against Design Stock
| 0.7 | GILD | Gilead Sciences Earnings Call Tomorrow | PairCorr |
| 0.64 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.47 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Design Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Design Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Design Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Design Therapeutics to buy it.
The correlation of Design Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Design Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Design Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Design Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Design Therapeutics Piotroski F Score and Design Therapeutics Altman Z Score analysis. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.Note that the Design Therapeutics information on this page should be used as a complementary analysis to other Design Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Design Stock analysis
When running Design Therapeutics' price analysis, check to measure Design Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Design Therapeutics is operating at the current time. Most of Design Therapeutics' value examination focuses on studying past and present price action to predict the probability of Design Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Design Therapeutics' price. Additionally, you may evaluate how the addition of Design Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Design Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Revenue Per Share 0.001 | Return On Assets (0.15) | Return On Equity (0.22) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.